A Gut target trial emulation study indicated that diabetes patients diagnosed with hepatocellular carcinoma who began treatment with a GLP-1 agonist demonstrated a longer time until cancer recurrence. These patients also experienced improved survival rates when compared to those who started treatment with a DPP-4 inhibitor.

The study specifically focused on outcomes for individuals with both diabetes and hepatocellular carcinoma. It observed differences based on the initial type of medication used for diabetes management among this patient group.

Additional research from the Journal of Hepatology determined that chronic hepatitis B patients undergoing nucleos(t)ide analogue therapy for over a decade face a persistent elevated risk for hepatocellular carcinoma. Separately, a large prospective cohort study conducted in China and published in Clinical Gastroenterology and Hepatology found that all age groups are susceptible to increased diabetes risk among individuals with metabolic dysfunction-associated steatotic liver disease.

Furthermore, a validation study published in the Journal of Hepatology concerned a pan-elastography machine-learning model. This model can accurately predict clinically important portal hypertension in patients with compensated advanced chronic liver disease.